Serum 25-hydroxyvitamin D levels and survival in colorectal and breast cancer patients: Systematic review and meta-analysis of prospective cohort studies.
Eur J Cancer. 2014 Feb 27. pii: S0959-8049(14)00124-5. doi: 10.1016/j.ejca.2014.02.006.
Maalmi H1, Ordóñez-Mena JM1, Schöttker B1, Brenner H2.
1German Cancer Research Center (DKFZ), Division of Clinical Epidemiology and Aging Research, Im Neuenheimer Feld 581, 69120 Heidelberg, Germany.
2German Cancer Research Center (DKFZ), Division of Clinical Epidemiology and Aging Research, Im Neuenheimer Feld 581, 69120 Heidelberg, Germany; German Cancer Consortium (DKTK), Heidelberg, Germany. Electronic address: h.brenner at dkfz.de.
AIM:
To estimate the association between serum 25-hydroxyvitamin D (25(OH)D) levels and survival among colorectal and breast cancer patients.
METHODS:
We performed a comprehensive literature search of prospective cohort studies assessing the association of serum 25(OH)D levels with survival in colorectal and breast cancer patients. Study characteristics and results were extracted and dose-response relationships were graphically displayed in a standardised manner. Meta-analyses using random effects models were performed to estimate pooled hazard ratios.
RESULTS:
The systematic search yielded five studies including 2330 colorectal cancer patients and five studies including 4413 breast cancer patients all of which compared mortality across two to five categories of 25(OH)D levels.
Among colorectal cancer patients, pooled hazard ratios (95% confidence intervals) comparing highest with lowest categories were 0.71 (0.55-0.91) and 0.65 (0.49-0.86) for overall and disease-specific mortality, respectively.
For breast cancer patients, the corresponding pooled estimates were 0.62 (0.49-0.78) and 0.58 (0.38-0.84), respectively. No significant evidence of heterogeneity between studies was observed.
CONCLUSION:
Higher 25(OH)D levels (>75nmol/L) were associated with significantly reduced mortality in patients with colorectal and breast cancer. Randomised controlled trials are needed to evaluate whether vitamin D supplementation can improve survival in colorectal and breast cancer patients with low vitamin D status (25(OH)D<50nmol/L) at diagnosis and before treatment.
PMID: 24582912
See also ViatminDWiki
- Overview Cancer-Colon and vitamin D
- Cancer survival 4 percent more likely with just a little more vitamin D (4 ng) - meta-analysis July 2014
Studies in all 3 categories: Breast Cancer, Meta-analysis and Mortality
- Deaths from many types of Cancer associated with low vitamin D- review of meta-analyses Sept 2020
- Breast Cancer Mortality reduced 60 percent if more than 60 ng of Vitamin D – meta-analysis June 2017
- Cancer survival 4 percent more likely with just a little more vitamin D (4 ng) - meta-analysis July 2014
- Death due to breast cancer reduced 40 percent if high vitamin D – meta-analysis April 2014
- More survive Breast Cancer if more vitamin D – 2X fewer deaths with just 30 ng -meta-analysis March 2014
- Colorectal and Breast Cancer – Vitamin D is associated with fewer deaths – meta-analysis Feb 2014
- Breast Cancer survival 2X more likely if vitamin D sufficient – meta-analysis May 2013